FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

OMB APPROVAL								
OMB Number:	OMB Number: 3235-0104							
Estimated average burden								
hours per response:	0.5							

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* Opaleye Management Inc. 2. Date of Event Requiring Stateme (Month/Day/Year) 05/18/2015			nent	3. Issuer Name and Ticker or Trading Symbol Imprimis Pharmaceuticals, Inc. [IMMY]							
(Last) 9B RUSSELL	(First) STREET	(Middle)			4. Relationship of Reporti (Check all applicable) Director	on(s) to Issuer		5. If Amendment, Date of Original Filed (Month/Day/Year)			
(Street) CAMBRIDGE (City)	E MA (State)	02140 (Zip)			Officer (give title below)		Other (spe below)			cable Line) Form filed by	/Group Filing (Check y One Reporting Person y More than One erson
Table I - Non-Derivative Securities Beneficially Owned											
1. Title of Security (Instr. 4)				. Amount of Securities Beneficially Owned (Instr	4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)		4. Nature of Indirect Beneficial Ownership (Instr. 5)			
Imprimis Pharmaceuticals, Inc.					1,167,199		I		See Footnote ⁽¹⁾		
Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)											
1. Title of Derivative Security (Instr. 4) 2. Date Exercisal Expiration Date (Month/Day/Year		ate	and 3. Title and Amount of Securit Underlying Derivative Securit		ty (Instr. 4) Conve		ersion ercise	5. Ownership Form:	6. Nature of Indirect Beneficial Ownership (Instr. 5)		
			Date Exercisable	Expiration Date	n Title		Amount or Number of Shares	Price of Derivati Security	ve	Direct (D) or Indirect (I) (Instr. 5)	

Explanation of Responses:

1. Securities reported herein for Opaleye Management, Inc. (the "Company) represent Common Stock beneficially owned and held of record by the Company and Opaleye, L.P., a private fund for which the Company serves as the investment manager (the "Fund"). James Silverman is the President and sole shareholder of the Company. The Company, the Fund and Mr. Silverman (the "Reporting Persons") are each beneficial owners and have an address of 9B Russell Street, Cambridge, MA 02140. The Reporting Persons disclaim beneficial ownership, within the meaning of Section 16 of the Securities Exchange Act of 1934, as amended, or otherwise of such portion of the shares and warrants in which the Reporting Persons have no actual pecuniary interest therein.

James Silverman, individually 05/20/2015

<u>James Silverman, as Manager</u>

05/20/2015

of Opaleye GP LLC

00/20/2020

James Silverman, as President

05/20/2015

of Opaleye Management, Inc.** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.